Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 6, 2006, Pages 1931-1936

  Ba, Boubakar B ^a   Arpin, Corinne ^a   Vidaillac, Céline ^a,b   Chausse, Arnaud ^a   Saux, Marie Claude ^a   Quentin, Claudine ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b Laboratoire de Pharmacochimie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ETHIDIUM BROMIDE; GATIFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; ERADICATION THERAPY; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE;

EID: 33744502866     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01586-05     Document Type: Article

References (35)

1. Allen, G. P., G. W. Kaatz, and M. J. Rybak. 2003. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 47:2606-2614.
2. Ba, B. B., A. Bernard, A. Iliadis, C. Quentin, D. Ducint, R. Etienne, M. Fourtillan, I. Maachi-Guillot, and M. C. Saux. 2001. New approach for accurate simulation of human pharmacokinetics in an in vitro pharmacodynamic model: application to ciprofloxacin. J. Antimicrob. Chemother. 47:223-227.
3. Bergan, T., I. B. Carlsen, and J. E. Fuglesang. 1980. An in vitro model for monitoring bacterial responses to antibiotic agents under simulated in vivo conditions. Infection 8(Suppl. 1):S96-S102.
4. Bergogne-Berezin, E. 2002. Clinical role of protein binding of quinolones. Clin. Pharmacokinet. 41:741-750.
5. Booker, B. M., P. F. Smith, A. Forrest, J. Bullock, P. Kelchlin, S. M. Bhavnani, R. N. Jones, and P. G. Ambrose. 2005. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. Antimicrob. Agents Chemother. 49:1775-1781.
6. Bowker, K. E., M. Wootton, C. A. Rogers, R. Lewis, H. A. Holt, and A. P. MacGowan. 1999. Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin. J. Antimicrob. Chemother. 44:661-667.
7. Dong, Y., X. Zhao, J. Domagala, and K. Drlica. 1999. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1756-1758.
8. Ellner, P. D., and H. C. Neu. 1981. The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. JAMA 246:1575-1578.
9. Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558.
10. Firsov, A. A., A. A. Shevchenko, S. N. Vostrov, and S. H. Zinner. 1998. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob. Agents Chemother. 42:659-665.
11. Firsov, A. A., S. N. Vostrov, A. A. Shevchenko, and G. Cornaglia. 1997. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 41:1281-1287.
12. Fish, D. N., and D. S. North. 2001. Gatifloxacin, an advanced 8-methoxy fluoroquinolone. Pharmacotherapy 21:35-59.
13. Fournier, B., R. Aras, and D. C. Hooper. 2000. Expression of the multidrug resistance transporter NorA from Staphylococcus aureus is modified by a two-component regulatory system. J. Bacteriol. 182:664-671.
14. Fukuda, H., S. Hori, and K. Hiramatsu. 1998. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone. against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob. Agents Chemother. 42:1917-1922.
15. Gumbo, T., A. Louie, M. R. Deziel, and G. L. Drusano. 2005. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill hut to rapid emergence of resistance. Antimicrob. Agents Chemother. 49:3178-3181.
16. Hooper, D. C. 2002. Fluoroquinolone resistance among gram-positive cocci. Lancet Infect. Dis. 2:530-538.
17. Hosaka, M., T. Yasue, H. Fukuda, H. Tomizawa, H. Aoyama, and K. Hirai. 1992. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob. Agents Chemother. 36:2108-2117.
18. Ince, D., R. Aras, and D. C. Hooper. 1999. Mechanisms and frequency of resistance to gatifloxacin in comparison with ciprofloxacin in Staphylococcus aureus. Drugs 58(Suppl. 2):134-135.
19. Ince, D., and D. C. Hooper. 2001. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 45:2755-2764.
20. Ito, H., H. Yoshida, M. Bogaki-Shonai, T. Niga, H. Hattori, and S. Nakamura. 1994. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob. Agents Chemother. 38:2014-2023.
21. Kaatz, G. W., F. McAleese, and S. M. Seo. 2005. Multidrug resistance in Staphylococcus aureus due to overexpression of a novel multidrug and toxin extrusion (MATE) transport protein. Antimicrob. Agents Chemother. 49:1857-1864.
22. Kaatz, G. W., S. M. Seo, and C. A. Ruble. 1993. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 37:1086-1094.
23. Kaatz, G. W., R. V. Thyagarajan, and S. M. Seo. 2005. Effect of promoter region mutations and mgrA overexpression on transcription of norA, which encodes a Staphylococcus aureus multidrug efflux transporter. Antimicrob. Agents Chemother. 49:161-169.
24. LaCreta, F. P., S. Kaul, G. D. Kollia, G. Duncan, D. M. Randall, and D. M. Grasela. 2000. Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults. Pharmacotherapy 20:59S-66S.
25. MacGowan, A. P., K. E. Bowker, M. Wootton, and H. A. Holt. 1999. Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and Streptococci of lancefield groups A and G. J. Antimicrob. Chemother. 44:761-766.
26. Madaras-Kelly, K. J., B. E. Ostergaard, L. B. Hovde, and J. C. Rotschafer. 1996. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 40:627-632.
27. Naber, C. K., M. Steghafner, M. Kinzig-Schippers, C. Sauber, F. Sorgel, H. J. Stahlberg, and K. G. Naber. 2001. Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers. Antimicrob. Agents Chemother. 45:293-297.
28. Ng, E. Y., M. Trucksis, and D. C. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1881-1888.
29. Nguyen, H. A., J. Grellet, B. B. Ba, C. Quentin, and M. C. Saux. 2004. Simultaneous determination of levofloxacin, gatifloxacin and moxifloxacin in serum by liquid chromatography with column switching. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 810:77-83.
30. Schmitz, F. J., A. C. Fluit, S. Brisse, J. Verhoef, K. Kohrer, and D. Milatovic. 1999. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol. Med. Microbiol. 26:281-287.
31. Schmitz, F. J., M. E. Jones, B. Hofmann, B. Hansen, S. Scheuring, M. Luckefahr, A. Fluit, J. Verhoef, U. Hadding, H. P. Heinz, and K. Kohrer. 1998. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob. Agents Chemother. 42:1249-1252.
32. Takei, M., H. Fukuda, R. Kishii, and M. Hosaka. 2001. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45:3544-3547.
33. Takenouchi, T., C. Ishii, M. Sugawara, Y. Tokue, and S. Ohya. 1995. Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob. Agents Chemother. 39:1414-1418.
34. Truong-Bolduc, Q. C., P. M. Dunman, J. Strahilevitz, S. J. Projan, and D. C. Hooper. 2005. MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J. Bacteriol. 187:2395-2405.
35. Wang, T., M. Tanaka, and K. Sato. 1998. Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains. Antimicrob. Agents Chemother. 42:236-240.